Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
IHE vs VHT: Weighing a Concentrated Pharma ETF Against Broad Health Care Exposure

IHE vs VHT: Weighing a Concentrated Pharma ETF Against Broad Health Care Exposure

Key Takeaways

  • IHE is a concentrated, single-industry bet on U.S. pharmaceutical manufacturers, while VHT spans the entire U.S. health care sector.
  • IHE holds roughly 57 stocks with about 80% of assets in its top 10; VHT holds roughly 417 stocks, sharply reducing single-name concentration risk.
  • Cost structure favors VHT: a 0.09% expense ratio versus 0.37% for IHE, a meaningful long-term drag differential.
  • IHE's top holdings are dominated by LLY and JNJ (together near 45% of assets), amplifying single-stock and patent-cycle exposure.
  • VHT adds exposure to biotech, managed care, medical devices, and life-science tools that IHE simply does not hold.
  • Tickeron AI Verdict: VHT — superior cost efficiency, diversification, and structural balance make it the favored choice.

Introduction

Health care remains one of the largest and most resilient sectors in the U.S. equity market, but the two ETFs examined here take very different approaches to it. The iShares U.S. Pharmaceuticals ETF (IHE) and the Vanguard Health Care ETF (VHT) do not compete head-to-head so much as they provide distinct exposure profiles within the same broad industry. IHE offers high-conviction, single-industry exposure for investors seeking pure-play access to drug makers. VHT delivers a broad, market-cap-weighted portfolio that captures the full health care spectrum, from pharmaceuticals to insurers and medical technology. Comparing their structures, costs, and risk characteristics helps clarify which version of health care exposure aligns better with a given portfolio.

iShares U.S. Pharmaceuticals ETF (IHE) Overview

IHE is a passively managed fund that tracks the Dow Jones U.S. Select Pharmaceuticals Index, a free-float-adjusted, market-capitalization-weighted benchmark focused on U.S. pharmaceutical companies, including prescription drug, over-the-counter, and vaccine makers. The fund holds roughly 57 positions and is highly concentrated, with the top 10 names typically accounting for around 80% of assets. LLY and JNJ each exceed 20% of the portfolio, followed by VTRS, RPRX, ZTS, PFE, MRK, and BMY. Nearly all exposure sits in the pharmaceuticals industry, with negligible cash. Its expense ratio stands at 0.37%. This setup makes IHE a high-conviction, single-theme vehicle whose returns depend heavily on drug-pricing dynamics, patent cycles, and a handful of large weight-loss and immunology franchises. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Vanguard Health Care ETF (VHT) Overview

VHT is a passively managed fund that tracks the MSCI US Investable Market Health Care 25/50 Index, a benchmark covering large-, mid-, and small-cap U.S. health care stocks under the Global Industry Classification Standard. The fund holds roughly 417 securities, providing exposure across pharmaceuticals, biotechnology, managed care, health care equipment and supplies, and life-science tools. Its largest positions include LLY (around 13%), JNJ, ABBV, MRK, UNH, TMO, AMGN, GILD, ABT, and PFE. Its expense ratio is just 0.09%, among the lowest in the category. The 25/50 methodology caps single-stock weights, preventing any one name from dominating returns and creating a more balanced profile.

Industry and Thematic Backdrop

Both funds operate in a health care sector shaped by several overlapping forces. Innovation in GLP-1 weight-loss and metabolic therapies has driven outsized gains for a small number of large pharmaceutical franchises, disproportionately benefiting IHE’s concentrated portfolio. At the same time, policy debates around drug pricing, Medicare negotiations, and regulatory scrutiny of pharmacy benefit managers continue to influence sentiment across manufacturers and managed-care providers. Higher-for-longer interest-rate expectations have pressured biotechnology valuations, given their reliance on long-dated cash flows, while defensive, cash-generative large-cap pharma and device makers have shown relative resilience. The broader backdrop features a clear bifurcation: a few high-growth names command premium valuations, while diversified health care companies trade on steadier fundamentals.

Performance and Positioning Comparison

Over recent market cycles, IHE’s concentrated exposure to mega-cap pharmaceutical leaders has amplified both upside and downside relative to the wider sector. When GLP-1 and immunology leaders rally, IHE tends to outperform; when single-name earnings disappointments or pricing headlines emerge, its concentration magnifies volatility. VHT, by contrast, has delivered more moderate, diversified performance by blending pharma with managed care, biotech, and medical technology. Its broader holdings and lower beta profile have historically produced smoother positioning, with less sensitivity to any single company’s clinical or regulatory news. On a cost-adjusted basis, VHT’s 0.09% expense ratio compounds favorably over time versus IHE’s 0.37%, a structural edge that persists regardless of short-term sector rotation. Investors seeking tactical, high-beta pharma exposure may prefer IHE, while those prioritizing diversified, low-cost core health care positioning are better served by VHT.

Using Tickeron’s AI Screener for ETF Research

Tickeron’s AI Screener has become a regular part of my process when comparing sector ETFs. The tool lets me quickly filter by industry, holdings concentration, expense ratios, and technical signals, helping confirm whether a concentrated vehicle like IHE or a broader one like VHT better matches current portfolio needs. It surfaces relevant comparisons efficiently without replacing my own analysis.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would currently favor VHT over IHE. VHT offers a materially lower expense ratio (0.09% versus 0.37%), substantially broader diversification across roughly 417 holdings, and exposure to multiple health care sub-industries that can offset weakness in any single segment. Its 25/50 weighting constraints reduce single-name concentration risk, whereas IHE’s heavy dependence on two mega-cap drug makers concentrates both opportunity and vulnerability. While IHE may outperform during strong, narrow pharma momentum phases, VHT’s combination of cost efficiency, diversification, and balanced risk exposure presents a more consistent, probabilistically favorable structure for broad health care positioning.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IHE, VHT

IHE in upward trend: 10-day moving average crossed above 50-day moving average on October 28, 2026

The 10-day moving average for IHE crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on IHE as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for IHE just turned positive on October 15, 2026. Looking at past instances where IHE's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.

IHE moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHE advanced for three days, in 286 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 246 of 288 cases where IHE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for IHE moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 26 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

IHE broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN).

Industry description

The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares U.S. Pharmaceuticals ETF (IHE) ETF is 63.11B. The market cap for tickers in the group ranges from 31.04M to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is EYPT at 31.04M.

High and low price notable news

The average weekly price growth across all stocks in the iShares U.S. Pharmaceuticals ETF (IHE) ETF was 4%. For the same ETF, the average monthly price growth was 12%, and the average quarterly price growth was 27%. LQDA experienced the highest price growth at 29%, while EYPT experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the iShares U.S. Pharmaceuticals ETF (IHE) ETF was -38%. For the same stocks of the ETF, the average monthly volume growth was -32% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 52
Price Growth Rating: 46
SMR Rating: 74
Profit Risk Rating: 68
Seasonality Score: 13 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.